Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 10/20 | 0.64 |
| ▸ | MMP2 | P08253 | 10/20 | 0.64 |
| ▸ | MMP9 | P14780 | 10/20 | 0.64 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14515854 | 0.87 | MEN1 (0.62) | MMP1MMP2MMP9TRPM2MAPT | |
| SCHEMBL9973849 | 0.87 | MMP1 (0.63) | MMP1MMP2MMP9TRPM2TRPA1 | |
| SCHEMBL10005257 | 0.85 | MMP1 (0.66) | MMP1MMP2MMP9GAAMAPT | |
| SCHEMBL16705449 | 0.85 | MMP1 (0.59) | MMP1MMP2MMP9TRPM2GAA | |
| SCHEMBL14290081 | 0.85 | MMP1 (0.64) | MMP1MMP2MMP9GAAMAPT | |
| SCHEMBL14289937 | 0.84 | MMP1 (0.65) | MMP1MMP2MMP9TRPM2MAPT | |
| SCHEMBL30538697 | 0.83 | MMP1 (0.75) | MMP1MMP2MMP9TRPM2GAA | |
| SCHEMBL30335821 | 0.83 | MMP1 (0.75) | MMP1MMP2MMP9TRPM2GAA | |
| SCHEMBL2851499 | 0.83 | MMP1 (0.75) | MMP1MMP2MMP9TRPM2GAA | |
| SCHEMBL2851492 | 0.83 | MMP1 (0.75) | MMP1MMP2MMP9TRPM2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| WO-2007062957-A1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | SYMRISE GMBH & CO. KG (DE) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | OAT, PIGS, HLA-A | MMP1 3885/4885MMP2 3658/4885MMP9 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.